Your trusted guide to clinical trials
Find clinical trials relevant to you, near you. Powered by AI.
Become a Research Volunteer.
Get notified about future clinical trial opportunities.
Browse Trials by Condition
- Barrett's Esophagus 2,783
- Neoplasms 1,209
- Lymphocytic Leukemia, Acute 1,015
- Metastatic Cancer 753
- Neoplasm Metastasis 751
- Menstruation 643
- Surgery 549
- Lung Disease 521
- Allergy 501
- Uterine Fibroids 429
- Neurologic Disorders 415
- Pain 381
- Viral Infections 348
- Chemotherapy 331
- Wounds 305
- Vision Loss 271
- Vascular Diseases 254
- Asthma 251
- Metabolic Disorders 216
- Heart Disease 212
- Diabetes Mellitus, Type 2 210
TrialX — your clinical trial finder
A new, easy way to participate in clinical studies.
New & updated studies
Browse all studies
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.Study details include:Screening period (up to 4 weeks).Treatment period (up to 16 …
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome …
Gabriel Study_90000
What is the purpose of this study?Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 …
Isbah: SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC (HP-SIB-AHFRT)
This is a prospective, single-arm, single-center phase I/II clinical trial evaluating the safety, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of simultaneous integrated boost accelerated hyperfractionated radiotherapy in patients with high-proliferation non-small cell lung cancer (NSCLC).
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM).The names of the study drugs and vaccine involved in this study are:DC/MM fusion vaccine (a personalized …
Three-Dimensional Bone Augmentation of Severely Atrophied Posterior Mandibular Alveolar Ridges Using Customized-3D Zirconia Barriers Versus Pre-bent Titanium Mesh
Zirconia can be considered as an alternative and innovative material suitable for GBR because it has high biocompatibility, together with a scarce tissue integration. Zirconia barriers could be a predictable and alternative barrier material for GBR in terms of (i) biocompatibility, (ii) ease of use and removal, (iii) exposure management, …
Your clinical trial journey
Find a study
Search or browse for a clinical trial near you.
Check Eligibility
Learn more about the study and check to see if you are eligible to take part in it.
Participate
If you prequalify, connect with the study team and let your trial begin!
Accelerating clinical research powered by AI
Building patient connection for a better future
Join us in our mission to help accelerate clinical research.
We are on a mission to make 1 billion actions made towards clinical research. ‘Actions’ are anything from searching for trials, sharing a trial, getting in touch with a study team — or something as simple as becoming a volunteer.